Approval · Notice of Compliance 34705 · 2025
IMFINZI: Notice of Compliance 34705
Issued January 17, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 34705
- Date
- January 17, 2025
- Company
- Astrazeneca Canada IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New Indication: Endometrial Cancer Imfinzi in combination with carboplatin and paclitaxel is indicated for the first-line treatm0ent of adult patients with primary advanced or recurrent mismatch repair deficient (dMMR) endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with Imfinzi as monotherapy
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| IMFINZI | Not yet assigned | — |
Medicinal ingredients
- DURVALUMAB 50 MG per ML